Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma, Inc. (Nasdaq: SILO) regularly issues news updates that reflect its dual identity as a developmental-stage biopharmaceutical company and a cryptocurrency treasury company. Its press releases highlight progress in drug development for stress-induced psychiatric disorders, chronic pain, and central nervous system diseases, alongside announcements about its evolving digital assets treasury strategy.
On the biopharmaceutical side, Silo’s news flow centers on SPC-15, an investigational intranasal serotonin 5-HT4 receptor agonist being developed for PTSD and stress-induced anxiety. Recent releases describe IND-enabling toxicology and toxicokinetic work, large animal safety studies, drug-device evaluations of a soft mist nasal spray system, and plans for Phase 1 single ascending dose and multiple ascending dose studies. The company also reports on regulatory strategy, including its intention to pursue the FDA’s 505(b)(2) pathway, and on collaborations with organizations such as Allucent and Columbia University.
News items also cover Silo’s broader pipeline, including SP-26 for fibromyalgia and chronic pain and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Investors following SILO news can expect updates on preclinical data, clinical trial preparations, intellectual property expansion, and strategic academic and CRO partnerships.
In parallel, Silo’s releases describe the launch and build-out of its digital assets treasury. Announcements detail initial purchases of Bitcoin, Ethereum, Solana, and ResearchCoin, the establishment of a Crypto Advisory Board, engagement of Fireblocks for institutional-grade custody and infrastructure, and allocation to the Alphaledger T12 Fund for tokenized real-world asset exposure on the Solana blockchain. Additional disclosures include software and domain acquisitions related to crypto applications and updates on treasury diversification objectives.
Visitors to the SILO news page can use this stream of company-issued information to track clinical milestones, regulatory steps, capital markets activity, and digital asset strategy developments over time.
Silo Pharma (Nasdaq: SILO) announced a non-binding Letter of Intent dated Dec. 30, 2025 with Allucent (US) LLC to support Phase 1 clinical development of SPC-15 nasal spray.
The LOI covers planning for two planned Phase 1 studies in healthy subjects: an open-label Single Ascending Dose (SAD) study and an open-label Multiple Ascending Dose (MAD) study. Allucent and Silo intend to negotiate a Master Services Agreement and project-specific Work Order covering clinical operations, pharmacovigilance, data management, biostatistics, clinical pharmacology modeling & simulation, and medical writing.
The LOI outlines proposed payment terms, including an upfront amount for direct service fees and pass-through costs to be reconciled against final invoices. Management described the LOI as a potential step toward generating safety and pharmacokinetic data for SPC-15.
Silo Pharma (Nasdaq: SILO) selected Allucent, a global clinical research organization, to support final preparations and its planned FDA IND submission in 2026 for a Phase 1 first-in-human trial of intranasal SPC-15 as a therapeutic for PTSD.
The company expects IND-enabling GLP toxicology/toxicokinetic data and a drug-device study for its formulation-specific intranasal spray system in early 2026, and intends to pursue the FDA’s 505(b)(2) accelerated pathway. Trial start is contingent on FDA IND approval; Silo described Allucent’s role as preparing dose-ranging protocols to assess SPC-15 pharmacokinetics and safety.
Silo Pharma (NASDAQ: SILO) announced on October 29, 2025 that it selected the Alphaledger/Simplify Target 12% Distribution Fund (Alphaledger T12 Fund) as a core element of its tokenized real-world asset (RWA) strategy on the Solana blockchain.
The fund is described as a digital-native vehicle focused on tokenized RWAs, offering high monthly income via a mix of high-yield, low-duration fixed income, hedged credit, and options strategies while leveraging Solana for high-speed, low-cost execution.
Silo framed the allocation as a treasury diversification move intended to generate yield and reduce portfolio volatility while integrating decentralized infrastructure with its crypto and fintech initiatives.
Silo Pharma (NASDAQ: SILO) reported progress on its lead PTSD candidate SPC-15 and launched a digital assets treasury program. Key biopharma updates include positive bioanalytical and large-animal safety/toxicology results for a 7-day study, completion of an IND-enabling GLP toxicology/toxicokinetic study (data expected in early 2026), finalizing a drug-device study for a microchip-based nasal spray, and patent expansion in the U.S., Australia and Japan. On the crypto side, Silo began purchases in Sept–Oct 2025 (BTC, ETH, SOL, RSC), appointed a lead crypto advisor, formed a crypto advisory board, and engaged Fireblocks for institutional custody and operations.
Catalysts include FDA follow-up in November 2025 and IND submission planning in 2026.
Silo Pharma (NASDAQ: SILO) announced on October 8, 2025 its initial purchase of Bitcoin as part of a crypto reserve strategy aimed at multi-chain asset growth. The company said this purchase complements earlier crypto buys in Ethereum, RSC, and Solano tokens and signals conviction in Bitcoin as a store of value and a hedge against market volatility. Management indicated Silo will continue building a diversified digital-asset treasury to support the company’s multi-chain growth approach.
Silo Pharma (NASDAQ: SILO) announced on October 6, 2025 that it purchased ResearchCoin (RSC) as part of an expanded digital-assets treasury strategy to gain exposure to decentralized science (DeSci).
RSC is the native token of ResearchHub, a platform co-founded in 2019 by Coinbase CEO Brian Armstrong, designed to reward sharing, peer review, and curation of scientific knowledge. Silo characterized the move as an effort to diversify assets and participate in token-based models that could unlock value in the global research economy through tokenization of funding and intellectual property.
The announcement frames DeSci as a long-term growth opportunity that could allow earlier liquidity and exit options for research-backed innovations, but the company did not disclose the size, valuation, or timing of the RSC purchase.
Silo Pharma (NASDAQ:SILO), a developmental stage biopharmaceutical company, has completed its previously announced registered direct offering, raising $2.5 million in gross proceeds. The offering consisted of 2,857,143 shares of common stock priced at $0.875 per share.
In a concurrent private placement, the company issued unregistered warrants to purchase up to 2,857,143 shares at an exercise price of $0.75 per share. The warrants are immediately exercisable and will expire five years after the registration statement becomes effective. H.C. Wainwright & Co. served as the exclusive placement agent, and the proceeds will be used for working capital and general corporate purposes.
Silo Pharma (Nasdaq: SILO), a developmental stage biopharmaceutical company, has announced a $2.5 million registered direct offering priced at-the-market under Nasdaq rules. The company will sell 2,857,143 shares of common stock at $0.875 per share.
Additionally, Silo will issue unregistered warrants in a concurrent private placement to purchase up to 2,857,143 shares at an exercise price of $0.75 per share. These warrants will be immediately exercisable and expire after five years. The offering, managed by H.C. Wainwright & Co. as exclusive placement agent, is expected to close around October 1, 2025.
The company plans to use the net proceeds for working capital and general corporate purposes.
Silo Pharma (Nasdaq: SILO), a developmental-stage biopharmaceutical and cryptocurrency treasury company, has initiated implementation of its strategic agreement with Fireblocks for crypto treasury management. Fireblocks, a leading digital asset custody platform, has facilitated over $10 trillion in secure transfers to date.
The partnership aims to establish institutional-grade infrastructure for buying, staking, and managing digital assets at scale. Fireblocks' multi-layer security framework incorporates multi-party computation technology, Intel SGX, a signature policy engine, and deposit address authentication network.
Silo Pharma (Nasdaq: SILO), a developmental-stage biopharmaceutical and cryptocurrency treasury company, has partnered with Fireblocks as its institutional crypto treasury platform custodian. The strategic agreement aims to enhance Silo's digital asset management capabilities for Bitcoin, Ethereum, and Solana.
Fireblocks, which has facilitated over $6 trillion in secure transfers, will provide enterprise-grade security through its multi-layer framework, combining multi-party computation technology, Intel SGX, and deposit address authentication. This infrastructure will support Silo's long-term strategy for buying, staking, trading, and managing digital assets.
FAQ
What is the current stock price of Silo Pharma (SILO)?
What is the market cap of Silo Pharma (SILO)?
